General Cardiology

Our research work in general cardiology offers the most current, up-to-date novel therapies to patients. 

The Importance of Research in General Cardiology

We're always assessing treatment options and continuously improving standard therapy. Common conditions and needs that fall under this research area are:

Research allows us to continue to improve how we treat patients with cardiovascular disease, including the prevention of future heart attacks and strokes by improving blood pressure and/or cholesterol levels.

Research allows us to continue to think outside of the box to provide the most optimal care to our patients.

General Cardiology at MHIF

The Importance of Research in General Cardiology

Research allows us to continue to improve on how we treat patients with cardiovascular disease, whether it is to help prevent any future heart attacks, strokes, help improve blood pressure or cholesterol levels. Research allows us to continue to think outside of the box to provide the most optimal care to our patients.

Conferece Speaker Icon

Major Contributions

Our team has contribute to the Amgen Evolocumab (Repatha®) PCSK9i trial. Newest hot therapy and indication being studied is Lipoprotein (a) (Lp(a)).

Conferece Speaker Icon

Examples of Research

Statins, ASA, BP meds, BB trials, fish oil trials. Lp(a) studies, renal denervation, PCSK9i, myocarditis research.

Leadership in Pericarditis Research

We enroll nearly 1,000 research participants every year, providing hope for patients through options that may only be available because of research, which crosses all areas of cardiovascular health and care. In the area of general cardiology, some of our latest research has focused on pericarditis, which is swelling and irritation of the tissue surrounding the heart (pericardium).

Dr. David Lin leads the pericarditis research at MHIF and has published in leading cardiovascular journals, including the New England Journal of Medicine. This research was a Phase I multi center study of a new option for patients with acute symptoms of recurrent pericarditis. This is an important example of world-class research at MHIF that also contributes to the process to achieve regulatory approval of new treatments for patients.

Old man smiling

Make a Life-Changing Donation

Transformative research leads to extraordinary outcomes that are saving lives. All gifts advance care. 

Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.